In.Pact 5-year data
The In.Pact DCB, made by Medtronic (NYSE:MDT), was observed in the In.Pact Global Study, a large, prospective, multicenter, single-arm study across 64 international sites. Subjects included those with bilateral disease, multiple lesions, TASC, in-stent restenosis, long lesions and chronic total occlusions.
Five-year data, using the Kaplan-Meier method, included freedom from clinically-driven target lesion revascularization, a safety composite and all-cause death. The method estimated freedom from CD-TLR through five years was 69.4%, while the primary safety endpoint was at 67.4% and freedom from all-cause death was 78.9%.
According to the VIVA Physicians news release, since the results were published, safety and effectiveness through five years have been sustained and the outcomes support the use of the In.Pact Admiral DCB for managing real-world patients.